Phase I Trial of Belinostat in Combination with 13-cis-Retinoic Acid in Advanced Solid Tumor Malignancies: A California Cancer Consortium NCI/CTEP Sponsored Trial.

PURPOSE: The reported maximum tolerated dose (MTD) of single agent belinostat is 1000 mg/m(2) given days 1-5, every 21 days. Pre-clinical evidence suggests histone deacetylase inhibitors enhance retinoic acid signaling in a variety of solid tumors. We conducted a phase I study of belinostat combined...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Chemother Pharmacol
Main Authors: Luu, Thehang, Frankel, Paul, Beumer, Jan H, Lim, Dean, Cristea, Mihaela, Appleman, Leonard J, Lenz, Heinz J, Gandara, David R, Kiesel, Brian F, Piekarz, Richard L, Newman, Edward M
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6821594/
https://ncbi.nlm.nih.gov/pubmed/31522242
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-019-03955-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados